EverSource Wealth Advisors LLC Has $202,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1,371.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,165 shares of the company’s stock after buying an additional 8,542 shares during the period. EverSource Wealth Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Atria Investments Inc raised its position in shares of Teva Pharmaceutical Industries by 135.4% in the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company’s stock valued at $556,000 after buying an additional 17,746 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 1,928,715 shares of the company’s stock worth $34,755,000 after acquiring an additional 21,764 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in Teva Pharmaceutical Industries by 68.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company’s stock worth $584,000 after acquiring an additional 13,215 shares during the last quarter. CIBC Asset Management Inc grew its holdings in Teva Pharmaceutical Industries by 5.7% during the 3rd quarter. CIBC Asset Management Inc now owns 105,463 shares of the company’s stock worth $1,900,000 after acquiring an additional 5,713 shares during the last quarter. Finally, Claro Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $227,000. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TEVA shares. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.38 on Monday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company’s fifty day moving average price is $18.28 and its two-hundred day moving average price is $18.29. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a market cap of $18.57 billion, a price-to-earnings ratio of -11.29, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.